Spots Global Cancer Trial Database for Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Official Title: Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
Study ID: NCT01825395
Conditions
Interventions
Study Description
Brief Summary: To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado, Aurora, Colorado, United States
Contact Details
Name: Steven P Ringel, MD
Affiliation: University of Colorado, Denver
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
